ERBB2 and breast carcinoma: While 11PS04 has a relevant antitumor profile in the luminal cell model of breast CSCs, its activity against Her-2/Neu tumor derived cells (MMTV-neu+/+), a subtype of breast cancer with a poor prognosis that affects about 30% of patients, is also noteworthy.